Submandibular salivary gland transfer for the prevention of radiation-induced xerostomia in patients with nasopharyngeal carcinoma: 5-Year outcomes

Head and Neck

Volumn 33, Issue 3, 2011, Pages 389-395

  Liu, Xue Kui ^a   Su, Yong ^a   Jha, Naresh ^b   Hong, Ming Huan ^a   Mai, Hai Qiang ^a   Fan, Wei ^a   Zeng, Zong Yuan ^a   Guo, Zhu Ming ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

nasopharyngeal carcinoma; quality of life; radiation therapy; submandibular glas transfer; xerostomia prevention

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FREE TISSUE GRAFT; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION INDUCED XEROSTOMIA; SALIVA; SALIVARY GLAND FUNCTION; SUBMANDIBULAR GLAND; XEROSTOMIA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROSPECTIVE STUDIES; QUALITY OF LIFE; RADIATION INJURIES; REFERENCE VALUES; RISK ASSESSMENT; SALIVARY GLANDS; STATISTICS, NONPARAMETRIC; SUBMANDIBULAR GLAND; SURVIVAL ANALYSIS; TREATMENT OUTCOME; XEROSTOMIA;

EID: 79951698574     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21461     Document Type: Article

References (45)

1. Mossman K, Shatzman A, Chencharick J,. Long-term effects of radiotherapy on taste and salivary function in man. Int J Radiat Oncol Biol Phys 1982; 8: 991-997. (Pubitemid 12038677)
2. Fox PC, van Der Ven PF, Sonies BC, Weiffenbach JM, Baum BJ,. Xerostomia: evaluation of a symptom with increasing significance. J Am Dent Assoc 1985; 110: 519-525.
3. Liu XK, Zeng ZY, Hong MH, Zhang AL, Cui NJ, Chen FJ,. Clinical analysis of xerostomia in patients with nasopharyngeal carcinoma after radiation therapy. Chin J Cancer 2004; 23: 593-596.
4. Zimmerman RP, Mark RJ, Tran LM, Juillard GF,. Concomitant pilocarpine during head and neck irradiation reduces xerostomia. Int J Radiat Oncol Biol Phys 1997; 36: 571-575. (Pubitemid 27175312)
5. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N,. Prophylactic use of amifostine to prevent radiochemotherapy induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 52: 739-747. (Pubitemid 34158737)
6. Maes A, Weltens C, Flamen P, et al. Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol 2002; 63: 203-211. (Pubitemid 34628408)
7. Chao KS, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head and neck cancers receiving intensity-modulated or three dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001; 49: 907-916. (Pubitemid 32184597)
8. Jha N, Seikaly H, McGaw T, Coulter L,. Submandibular salivary gland transfer prevents radiation induced xerostomia. Int J Radiat Oncol Biol Phys 2000; 46: 7-11. (Pubitemid 30021472)
9. Seikaly H, Jha N, McGaw T, Coulter L, Liu R, Oldring D,. Submandibular gland transfer: a new method of preventing radiation-induced xerostomia. Laryngoscope 2001; 111: 347-352. (Pubitemid 32143759)
10. Saibishkumar E, Jha N, Scrimger R, et al. Parliament. Sparing the parotid glands and surgically transferred submandibular gland with helical tomotherapy in post-operative radiation of head and neck cancer: a planning study. Radiother Oncol 2007; 85: 98-104. (Pubitemid 47562588)
11. Jha N, Seikaly H, Harris J, et al. Submandibular salivary gland transfer procedure for the prevention of XRT induced xerostomia in patients with carcinoma of the nasopharynx. Radiother Oncol 2005; 76 (Suppl 1): S12.
12. Rieger J, Seikaly H, Jha N, et al. Submandibular gland transfer for prevention of xerostomia after radiation therapy. Arch Otolaryngol Head Neck Surg 2005; 131: 140-145. (Pubitemid 40204771)
13. Seikaly H, Jha N, Barnaby P, et al. Long term outcomes of submandibular gland transfer for the prevention of post-radiation xerostomia. Arch Otolaryngol Head Neck Surg 2004; 130: 956-961. (Pubitemid 39045603)
14. Jha N, Seikaly H, Harris J, et al. Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. Radiother Oncol 2003; 66: 283-289. (Pubitemid 36556047)
15. Liu R, Seikaly H, Jha N, et al. Anatomic study of submandibular gland transfer in an attempt to prevent postradiation xerostomia. J Otolaryngol 2002; 31: 76-79. (Pubitemid 34728667)
16. Liu XK, Zeng ZY, Hong MH, et al. Primary effect of submandibular salivary gland transfer in preventing radiation-induced xerostomia of nasopharyngeal carcinoma. Chin J Cancer 2005; 24: 577-581.
17. Kohn WG, Ship JA, Atkinson JC, Patton LL, Fox PC,. Salivary gland 99m Tc-scintigraphy: a grading scale and correlation with major gland flow rates. J Oral Pathol Med 1992; 21: 70-74.
18. Dawes C,. Circadian rhythms in the flow rate and composition of unstimulated and stimulated human submandibular saliva. J Physiol 1975; 244: 535-548.
19. Wijers OB, Levendag PC, Braaksma MM, Boonzaaijer M, Visch LL, Schmitz PI,. Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors. Head Neck 2002; 24: 737-747. (Pubitemid 34857299)
20. Milne RW, Dawes C,. The relative contributions of different salivary glands to the blood group activity of whole saliva in humans. Vox Sang 1973; 25: 298-307.
21. Dawes C,. Factor influencing salivary flow rate and composition. In:, Edgar WM, O'Mullane DM, editors. Saliva and oral health, 2nd ed. London: British Dental Association; 1996. pp 1-8.
22. Bohuslavizki KH, Klutmann S, Brenner W, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer. Strahlenther Onkol 1999; 175 (Suppl 4): 6-12. (Pubitemid 29526270)
23. Bohuslavizki KH, Klutmann S, Brenner W, Mester J, Henze E, Clausen M,. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. J Clin Oncol 1998; 16: 3542-3549. (Pubitemid 28506766)
24. Bohuslavizki KH, Brenner W, Klutmann S,. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. J Nucl Med 1998; 39: 1237-1242. (Pubitemid 28326158)
25. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18: 3339-3345.
26. Chamers MS, Garden AS, Rosenthal D, et al. Intensity modulated radiotherapy: is xerostomia still prevalent? Curr Oncol Rep 2005; 7: 131-136.
27. Eisbruch A, Rhodus N, Rosenthal D, et al. The prevention and treatment of radiotherapy induced xerostomia. Semin Radiat Oncol 2003; 13: 302-308. (Pubitemid 36962652)
28. Jabbari S, Kim HM, Feng M, et al. Matched case control study of quality of life and xerostomia after intensity modulated radiotherapy or standard radiotherapy for head and neck cancer: initial report. Int J Rad Oncol Biol Phys 2005; 63: 725-731. (Pubitemid 41400058)
29. Fang FM, Tsai WL, Chen HC, et al. Intensity-modulated or conformal radiotherapy improves the quality of life of patients with nasopharyngeal carcinoma: comparisons of four radiotherapy techniques. Cancer 2007; 109: 313-321.
30. Johnson JT, Ferretti GA, Nethery WJ, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993; 329: 390-395. (Pubitemid 23219343)
31. Zimmerman RP, Mark RJ, Tran LM, Juillard GF,. Concomitant pilocarpine during head and neck irradiation is associated with decreased post treatment xerostomia. Int J Rad Oncol Biol Phys 1997; 37: 571-575. (Pubitemid 27175312)
32. Rieke JW, Hafermann MD, Johnson JT, et al. Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials. Int J Rad Oncol Biol Phys 1995; 31: 661-669.
33. LeVeque FG, Montgomery M, Potter D, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 1993; 11: 1124-1131. (Pubitemid 23163354)
34. Scarantino C, LeVeque F, Swann RS, et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09 a phase III randomized study in head and neck cancer patients. J Support Oncol 2006; 4: 252-258.
35. Gornitsky N, Shenouda G, Sultanem K, et al. Double blind randomized, placebo controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98: 45-52. (Pubitemid 38953830)
36. Nyarday Z, Nemeth A, Ban A, et al. A randomized study to assess the effectiveness of orally administered pilocarpine during and after radiotherapy of head and neck cancer. Anticancer Res 2006; 26: 1557-1562.
37. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N,. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 52: 739-747. (Pubitemid 34158737)
38. Buntzel J, Kuttner K, Frohlich D, Glatzel M,. Selective cytoprotection with amifostine in concurrent radio chemotherapy for head and neck cancer. Ann Oncol 1998; 9: 505-509. (Pubitemid 28270638)
39. McDonald S, Meyerowitz C, Smudzin T, Rubin P,. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 1994; 29: 747-754. (Pubitemid 24241314)
40. Vardy J, Wong E, Izard M, Clifford A, Clarke SJ,. Life-threatening anaphylactoid reaction of amifostine used in concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review. Anticancer Drugs 2002; 13: 327-330. (Pubitemid 34492715)
41. Greenspan D, Daniels TE,. Effectiveness of pilocarpine in postradiation xerostomia. Cancer 1987; 59: 1123-1125. (Pubitemid 17040390)
42. Vitolo JM, Baum BJ,. The use of gene transfer for the protection and repair of salivary glands. Oral Dis 2002; 8: 183-191. (Pubitemid 34815223)
43. Rosenthal DI, Chambers MS, Weber RS, et al. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Semin Oncol 2004; 31 (Suppl 18): 25-28. (Pubitemid 40250140)
44. Saarilahti K, Kouri M, Collan J, et al. Erratum to Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer. Radiother Oncol 2006; 80: 107-108.
45. Kuten A, Ben-Aryeh H, Berdicevsky I, et al. Oral side effects of head and neck irradiation: correlation between clinical manisfestations and laboratory data. Int J Radiat Oncol Biol Phys 1986; 12: 401-405. (Pubitemid 16108870)